Boston Biomedical Inc. unblinded a global phase III study of its cancer stem cell pathway inhibitor, napabucasin, in advanced gastric and gastroesophageal junction cancer after the trial's data and safety monitoring board (DSMB) determined that combining napabucasin with paclitaxel is unlikely to yield better overall survival (OS) at 36 months than paclitaxel alone.
